Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formular Additional Discount Program

Solicitation No.

HT9402-25-Q-9403

Notice Type

Solicitation

Posted Date

September 2, 2025

Response Deadline

September 18, 2025

NAICS Code

325412AI guide

PSC / Class Code

6505

Contract Code

97DH

Issuing Office

DEFENSE HEALTH AGENCY

Sub-Agency

DEFENSE HEALTH AGENCY

Agency

DEPT OF DEFENSE

Primary Contact

Tracy Banks

City

AURORA

State

CO

ZIP Code

80011

AI Product/Service

product

The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2025 drug classes/subclass or newly approved drugs will be reviewed: a. Anzupgo – Atopy – Subclass: N/A b. Brinsupri - Pulmonary-1 Agents - Subclass: N/A c. Brynovin – Diabetes Non-Insulin – Subclass: DPP-4 Inhibitors d. Ekterly – Corticosteroids-Immune Modulators – Subclass: Hereditary Angioedema Agents e. Harliku – Metabolic Agents-Miscellaneous – Subclass: Replacement Enzymes f. Hernexeos – Oncological Agents – Subclass: N/A g. Kirsty – Insulins – Subclass: Rapid-Acting Agents U-100 h. Lopressor – Beta Blockers and Hydrochlorothiazide Combinations – Subclass: N/A i. Modeyso – Oncological Agents – Subclass: N/A j. Orlynvah – Antibiotics – Subclass: Beta-lactams k. Sephience – Metabolic Agents-Miscellaneous – Subclass: N/A The RFQ, including UF BPA and UF ADP appendices are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-25-Q-9403. Pre-quotation teleconference is on September 4, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.

1. September 2, 2025Posted Date
2. September 18, 2025Proposals / Responses Due